BR112015000161A2 - composições de vetor de vírus adeno-associado modificado - Google Patents
composições de vetor de vírus adeno-associado modificadoInfo
- Publication number
- BR112015000161A2 BR112015000161A2 BR112015000161A BR112015000161A BR112015000161A2 BR 112015000161 A2 BR112015000161 A2 BR 112015000161A2 BR 112015000161 A BR112015000161 A BR 112015000161A BR 112015000161 A BR112015000161 A BR 112015000161A BR 112015000161 A2 BR112015000161 A2 BR 112015000161A2
- Authority
- BR
- Brazil
- Prior art keywords
- associated virus
- virus vector
- vector compositions
- modified adeno
- adeno
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000945 filler Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668839P | 2012-07-06 | 2012-07-06 | |
| PCT/US2013/031644 WO2014007858A1 (en) | 2012-07-06 | 2013-03-14 | Modified adeno-associated virus vector compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015000161A2 true BR112015000161A2 (pt) | 2017-06-27 |
Family
ID=49882407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015000161A BR112015000161A2 (pt) | 2012-07-06 | 2013-03-14 | composições de vetor de vírus adeno-associado modificado |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9540659B2 (enExample) |
| EP (1) | EP2870237B1 (enExample) |
| JP (1) | JP6366581B2 (enExample) |
| CN (1) | CN104619832B (enExample) |
| AU (1) | AU2013287261B2 (enExample) |
| BR (1) | BR112015000161A2 (enExample) |
| CA (1) | CA2878401C (enExample) |
| ES (1) | ES2703177T3 (enExample) |
| HK (1) | HK1210214A1 (enExample) |
| IN (1) | IN2015KN00074A (enExample) |
| RU (1) | RU2679843C2 (enExample) |
| WO (1) | WO2014007858A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015KN00074A (enExample) * | 2012-07-06 | 2015-07-31 | Univ Iowa Res Found | |
| JP6663859B2 (ja) * | 2014-05-20 | 2020-03-13 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | ハンチントン病の治療化合物 |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN112553229A (zh) | 2014-11-05 | 2021-03-26 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
| EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| US20190000940A1 (en) * | 2015-07-31 | 2019-01-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of aadc deficiency |
| WO2017161273A1 (en) * | 2016-03-18 | 2017-09-21 | The Children's Hospital Of Philadelphia | Therapeutic for treatment of diseases including the central nervous system |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| BR112018073472A2 (pt) | 2016-05-18 | 2019-08-27 | Voyager Therapeutics, Inc. | composições e métodos de tratamento da doença de huntington |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN111108198A (zh) | 2017-05-05 | 2020-05-05 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
| AU2018338728B2 (en) | 2017-09-29 | 2025-01-02 | Centre National De La Recherche Scientifique (Cnrs) | Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery |
| US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| CN111479924B (zh) | 2017-10-16 | 2024-06-14 | 沃雅戈治疗公司 | 肌萎缩性侧索硬化症(als)的治疗 |
| CN111712569A (zh) * | 2017-12-11 | 2020-09-25 | 爱迪塔斯医药公司 | 用于基因编辑的Cpf1-相关方法和组合物 |
| US20190256867A1 (en) | 2018-02-01 | 2019-08-22 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| CN112041437A (zh) | 2018-02-19 | 2020-12-04 | 同源药物公司 | 用于恢复f8基因功能的腺相关病毒组合物和其使用方法 |
| MX2020010464A (es) | 2018-04-03 | 2021-01-29 | Vectores de virus que evitan anticuerpos. | |
| JP7425738B2 (ja) | 2018-04-03 | 2024-01-31 | ギンコ バイオワークス インコーポレイテッド | 眼組織を標的とするウイルスベクター |
| US12091435B2 (en) | 2018-04-03 | 2024-09-17 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| AU2019268330A1 (en) | 2018-05-15 | 2020-11-26 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
| US20210254103A1 (en) * | 2018-07-02 | 2021-08-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| EP3856762A1 (en) | 2018-09-28 | 2021-08-04 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| JP7698583B2 (ja) | 2019-03-21 | 2025-06-25 | ギンコ バイオワークス インコーポレイテッド | 組換えアデノ随伴ウイルスベクター |
| MX2021013913A (es) * | 2019-05-14 | 2022-03-17 | Univ Duke | Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa. |
| AR122285A1 (es) * | 2019-07-18 | 2022-08-31 | Lysogene | Composiciones y métodos para el tratamiento de la enfermedad de sanfilippo y otros trastornos |
| IL292297A (en) | 2019-10-17 | 2022-06-01 | Stridebio Inc | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| CN115768900A (zh) * | 2020-05-11 | 2023-03-07 | 戈迪安生物技术公司 | 病毒递送媒剂选择 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| CA3189878A1 (en) | 2020-08-19 | 2022-02-24 | Colin O'BANION | Adeno-associated virus vectors for treatment of rett syndrome |
| KR20230142576A (ko) * | 2021-02-05 | 2023-10-11 | 메이즈 테라퓨틱스, 인코퍼레이티드 | 스터퍼 폴리뉴클레오티드 서열을 포함하는 벡터 |
| US20240218397A1 (en) * | 2021-05-04 | 2024-07-04 | Regenxbio Inc. | Novel aav vectors and methods and uses thereof |
| CN119654414A (zh) * | 2022-08-09 | 2025-03-18 | 谢菲尔德大学 | 病毒载体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| JPH1033175A (ja) * | 1996-07-24 | 1998-02-10 | Hisamitsu Pharmaceut Co Inc | 組換えアデノ随伴ウイルスベクターの製造方法 |
| US6171855B1 (en) * | 1998-05-28 | 2001-01-09 | The Regents Of The University Of Michigan | Vectors |
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| WO2001032899A1 (en) * | 1999-10-29 | 2001-05-10 | Takara Shuzo Co., Ltd. | Gene transfer method |
| US7132277B1 (en) * | 2000-01-31 | 2006-11-07 | Merck & Co., Inc. | Helper dependent vector system for gene therapy |
| US7387896B2 (en) | 2003-03-26 | 2008-06-17 | The Regents Of The University Of Michigan | MicroRNA vectors |
| CA2543189A1 (en) * | 2003-10-20 | 2005-05-06 | Nsgene A/S | In vivo gene therapy of parkinson's disease |
| WO2009134681A2 (en) * | 2008-04-30 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Aav7 viral vectors for targeted delivery of rpe cells |
| CA2833905C (en) * | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
| ES2739804T3 (es) | 2011-02-12 | 2020-02-04 | Univ Iowa Res Found | Compuestos terapéuticos |
| IN2015KN00074A (enExample) * | 2012-07-06 | 2015-07-31 | Univ Iowa Res Found |
-
2013
- 2013-03-14 IN IN74KON2015 patent/IN2015KN00074A/en unknown
- 2013-03-14 ES ES13812649T patent/ES2703177T3/es active Active
- 2013-03-14 BR BR112015000161A patent/BR112015000161A2/pt not_active Application Discontinuation
- 2013-03-14 AU AU2013287261A patent/AU2013287261B2/en active Active
- 2013-03-14 CA CA2878401A patent/CA2878401C/en active Active
- 2013-03-14 CN CN201380035802.XA patent/CN104619832B/zh active Active
- 2013-03-14 WO PCT/US2013/031644 patent/WO2014007858A1/en not_active Ceased
- 2013-03-14 HK HK15110883.2A patent/HK1210214A1/xx unknown
- 2013-03-14 RU RU2015103901A patent/RU2679843C2/ru active
- 2013-03-14 EP EP13812649.5A patent/EP2870237B1/en active Active
- 2013-03-14 US US14/410,983 patent/US9540659B2/en active Active
- 2013-03-14 JP JP2015520166A patent/JP6366581B2/ja active Active
-
2017
- 2017-07-07 US US15/644,491 patent/US20170306355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2703177T3 (es) | 2019-03-07 |
| WO2014007858A1 (en) | 2014-01-09 |
| US20170306355A1 (en) | 2017-10-26 |
| CN104619832B (zh) | 2021-03-16 |
| CA2878401A1 (en) | 2014-01-09 |
| JP6366581B2 (ja) | 2018-08-08 |
| AU2013287261B2 (en) | 2019-03-07 |
| IN2015KN00074A (enExample) | 2015-07-31 |
| RU2015103901A (ru) | 2016-08-27 |
| US9540659B2 (en) | 2017-01-10 |
| HK1210214A1 (en) | 2016-04-15 |
| CA2878401C (en) | 2022-07-19 |
| RU2679843C2 (ru) | 2019-02-13 |
| EP2870237A1 (en) | 2015-05-13 |
| EP2870237A4 (en) | 2015-12-23 |
| AU2013287261A1 (en) | 2015-01-22 |
| JP2015522280A (ja) | 2015-08-06 |
| US20150184197A1 (en) | 2015-07-02 |
| EP2870237B1 (en) | 2018-09-26 |
| CN104619832A (zh) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015000161A2 (pt) | composições de vetor de vírus adeno-associado modificado | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| PT2755473T (pt) | Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações | |
| PT3061454T (pt) | Composições veterinárias orais parasiticidas compreendendo agentes activos de actuação sistémica, métodos e as suas utilizações | |
| BR112016003127A2 (pt) | composições e métodos para modular rna | |
| MY201504A (en) | Complement component c5 irna compositions and methods of use thereof | |
| SG10201804472YA (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| BR112014017021A2 (pt) | inibidores de irak e usos dos mesmos | |
| EA025278B9 (ru) | Антивирусная композиция против заключенных или незаключенных в оболочку днк- или рнк-вирусов | |
| MX362655B (es) | Composiciones cosmeticas. | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| HK1213585A1 (zh) | 烷基化环糊精组合物及其制备和使用方法 | |
| BR112015009989A2 (pt) | estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase | |
| BR112015022587A2 (pt) | formulações de citocina quimérica para entrega ocular | |
| EP2968385A4 (en) | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | |
| EP2900680A4 (en) | URIDEINDIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | |
| BR112015023387A2 (pt) | composições lipídicas de racecodotril | |
| DK3294756T3 (da) | Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er | |
| MX2019012375A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). | |
| ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| WO2013022550A3 (en) | Small molecule inhibitors of ebola and lassa fever viruses | |
| UA113540C2 (xx) | Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду | |
| EA201590790A1 (ru) | СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b | |
| BR112015002979B8 (pt) | Forma cristalina, e, composição farmacêutica | |
| EA201500203A1 (ru) | Композиция шампуня |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |